Výsledky vyhledávání - "Kwame Appenteng"

Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder:Findings from a Non-Interventional, Multinational, Cohort Study

Autor: Cheryl Enger, Libby Horter, Nina Sahlertz Kristiansen, Stefan de Vogel, Kelesitse Phiri, Brandon T. Suehs, Jesper Hallas, Alejandro Arana, Marie Linder, Ingvild Odsbu, Yihua Xu, Andrea V. Margulis, Kwame Appenteng, John D. Seeger, Morten Olesen, Veena Hoffman, Susana Perez-Gutthann

Publikováno v: Hoffman, V, Hallas, J, Linder, M, Margulis, A, Suehs, B T, Arana, A, Phiri, K, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Xu, Y, Kristiansen, N S, Appenteng, K, de Vogel, S, Seeger, J D & the mirabegron PMR-PASS study group 2021, ' Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder : Findings from a Non-Interventional, Multinational, Cohort Study ', Drug Safety, vol. 44, no. 8, pp. 899-915 . https://doi.org/10.1007/s40264-021-01095-7
Drug Safety

Introduction During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. Objective The purpose of this study was to compare incidence rates of adverse car

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606ed98949016a3becf28423411ba054
https://findresearcher.sdu.dk:8443/ws/files/191412893/Hoffman2021_Article_CardiovascularRiskInUsersOfMir.pdf

Zobrazit plný text záznamu

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

Autor: John D. Seeger, Marie Linder, Veena Hoffman, Alejandro Arana, Shahram Bahmanyar, Susana Perez-Gutthann, Jesper Hallas, Libby Horter, Brandon T. Suehs, Stefan de Vogel, Kelesitse Phiri, Nina Sahlertz Kristiansen, Andrea V. Margulis, Ingvild Odsbu, Kwame Appenteng, Cheryl Enger, Morten Olesen

Publikováno v: Phiri, K, Hallas, J, Linder, M, Margulis, A, Suehs, B, Arana, A, Bahmanyar, S, Hoffman, V, Enger, C, Horter, L, Odsbu, I, Olesen, M, Perez-Gutthann, S, Kristiansen, N S, Appenteng, K, de Vogel, S & Seeger, J 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion, vol. 37, no. 5, pp. 867-877 . https://doi.org/10.1080/03007995.2021.1891035
the Mirabegron PMR-PASS study group 2021, ' A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder ', Current Medical Research and Opinion . https://doi.org/10.1080/03007995.2021.1891035

Objective: This post-authorization safety study (EU PAS Register Number: EUPAS16088) was designedto compare the incidence of cancer outcomes in patients treated with mirabegron versus antimuscarinicmedications.Methods: Cohorts of mirabegron initiator

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e16fdb16219dfcf888757ab899a0540
https://pubmed.ncbi.nlm.nih.gov/33591859

Zobrazit plný text záznamu

Abstract 13154: Cardiovascular Risk in Users of Mirabegron Relative to Users of Antimuscarinic Treatments for Overactive Bladder: Findings From a Non-interventional, Real-world Data Safety Study

Autor: John D. Seeger, Stefan de Vogel, Andrea V. Margulis, Susana Perez Gutthann, Jesper Hallas, Kwame Appenteng, Brandon T. Suehs, Alejandro Arana, Morten S. Olesen, Nina Sahlertz Kristiansen, Cheryl Enger, Libby Horter, Veena Hoffman, Yihua Xu, Ingvild Odsbu, Marie Linder

Publikováno v: Circulation. 142

Introduction: During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased heart rate and systolic/diastolic blood pressure vs placebo in patients with overactive bladder (OAB). We studied the association between mi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1db0f2fc25a27e7aa2733f01192df96a
https://doi.org/10.1161/circ.142.suppl_3.13154

Zobrazit plný text záznamu

Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

Autor: Stefan de Vogel, Irene D. Bezemer, Daniel Dedman, Fabian Hoti, Noah Jamie Robinson, Daniel Prieto-Alhambra, Fernie J. A. Penning-van Beest, Helen P Booth, Minna Vehkala, Kwame Appenteng, Edith M. Heintjes, Ying He, Elisabeth Smits

Publikováno v: Clinical Epidemiology

Edith M Heintjes,1 Irene D Bezemer,1 Daniel Prieto-Alhambra,2,3 Elisabeth Smits,1 Helen P Booth,4 Daniel Dedman,4 Ying He,3 Fabian Hoti,5 Minna Vehkala,5 Stefan de Vogel,6 Noah Jamie Robinson,6 Kwame Appenteng,7 Fernie JA Penning-van Beest1 1PHARMO I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbbb49f8a966e3ab55144813c4da80c8
https://www.dovepress.com/evaluating-the-effectiveness-of-an-additional-risk-minimization-measur-peer-reviewed-article-CLEP

Zobrazit plný text záznamu

Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases

Autor: Milbhor D’Silva, Kwame Appenteng, Jason C. Simeone, Beth L. Nordstrom, Samuel Huse

Publikováno v: Drugs-Real World Outcomes

Background In 2014, the US Food and Drug Administration (FDA) initiated a prospective routine surveillance using the Mini-Sentinel (M-S) program to assess potential signals of acute myocardial infarction (AMI) and stroke with use of mirabegron, indic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a24426b1bd3d54c16d8b6c9d672ed0e
http://europepmc.org/articles/PMC5825387

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání